Ultravist: Safety and Efficacy in Computed Tomography of Head and Body
NCT ID: NCT00244140
Last Updated: 2014-02-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
435 participants
INTERVENTIONAL
2005-10-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast Enhanced Computed Tomography (CECT) of the Head and/or Body
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Ultravist in Patients Requiring CECT
NCT01415414
A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting
NCT02840903
Thoracoabdominal Arortic CTA Study
NCT02291718
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
NCT00876083
Safety Study of CZ10 in Healthy Volunteers
NCT06708767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Iopromide 370 mg I/mL
Iopromide (Ultravist 370 mg I/mL) administered intravenously
Iopromide 370 mg I/mL
Iopromide (Ultravist 370 mg I/mL) administered intravenously
Iopromide 300 mg I/mL
Iopromide (Ultravist 300 mg I/mL) administered intravenously
Iopromide 300 mg I/mL
Iopromide (Ultravist 300 mg I/mL) administered intravenously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iopromide 370 mg I/mL
Iopromide (Ultravist 370 mg I/mL) administered intravenously
Iopromide 300 mg I/mL
Iopromide (Ultravist 300 mg I/mL) administered intravenously
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson, Arizona, United States
Miami, Florida, United States
Tallahassee, Florida, United States
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Evanston, Illinois, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
New York, New York, United States
Stony Brook, New York, United States
Cleveland, Ohio, United States
Danville, Pennsylvania, United States
Charleston, South Carolina, United States
Medellín, Antioquia, Colombia
Bogotá, , Colombia
Mumbai-400026, , India
Tamil Nadu, , India
Seoul, Seoul Teugbyeolsi, South Korea
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
309660
Identifier Type: OTHER
Identifier Source: secondary_id
91462
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.